Tom 5, Nr 3 (2020)
COVID-19
Opublikowany online: 2020-06-02

dostęp otwarty

Wyświetlenia strony 306
Wyświetlenia/pobrania artykułu 347
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Propozycje modyfikacji w zakresie diagnostyki i leczenia skojarzonego raka piersi w okresie pandemii COVID-19

Aleksandra Łacko1, Adam Maciejczyk12, Piotr Kasprzak1, Dorota Dupla1, Elżbieta Senkus3, Wojciech Wysocki456, Zbigniew I. Nowecki7, Rafał Matkowski12
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2020;5(3):113-120.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020; 21(3): 335–337.
  2. Cortiula F, Pettke A, Bartoletti M, et al. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Annals of Oncology. 2020; 31(5): 553–555.
  3. Curigliano G, Cardoso M, Poortmans P, et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. The Breast. 2020; 52: 8–16.
  4. Zalecenia dla pacjentów onkologicznych w związku z sytuacją epidemiologiczną w kraju. NOWOTWORY J Oncol. 2020; 70(2): 37–38.
  5. Zalecenia Polskiego Towarzystwa Onkologicznego i Polskiego Towarzystwa Chirurgii Onkologicznej w sprawie postępowania z pacjentami onkologicznymi. NOWOTWORY J Oncol. 2020; 70(2): 39–40.
  6. Stanowisko Polskiego Towarzystwa Chirurgii Onkologicznej w sprawie postępowania u chorych na nowotwory wymagających leczenia chirurgicznego w okresie zagrożenia epidemiologicznego. NOWOTWORY J Oncol. 2020; 70(2): 41–42.
  7. Wysocki PJ, Kwinta Ł, Potocki P, et al. Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 – stanowisko Polskiego Towarzystwa Onkologii Klinicznej. NOWOTWORY J Oncol. 2020; 70(2): 43–46.
  8. Society of Breast Imaging Statement on Breast Imaging during the COVID-19 Pandemic. Society of Breast Imaging. https://www.sbi-online.org/Portals/0/Position%20Statements/2020/society-of-breast-imaging-statement-on-breast-imaging-during-COVID19-pandemic.pdf.
  9. Dietz J, Moran M, Isakoff S, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Research and Treatment. 2020; 181(3): 487–497.
  10. World Health Organization. COVID-19: Operational guidance for maintaining essential health services during an outbreak. https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak.
  11. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220.
  12. Cardoso F, Senkus E, Costa A, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology. 2018; 29(8): 1634–1657.
  13. American College of Surgeons. COVID-19 Guidelines for Triage of Breast Cancer Patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer.
  14. National comprehensive cancer network. Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community. https://www.nccn.org/covid-19/.
  15. The Treatment of Patients With Cancer and Containment of COVID-19: Experiences From Italy. Default Digital Object Group. 2020.
  16. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era.
  17. Coles CE, Aristei C, Bliss J, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology. 2020; 32(5): 279–281.
  18. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. European Journal of Cancer. 2015; 51(4): 451–463.
  19. Vrieling C, Werkhoven Ev, Maingon P, et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial. JAMA Oncol. 2017; 3(1): 42–48.
  20. Braunstein L, Gillespie E, Hong L, et al. Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints—Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States. Adv Radiat Oncol. 2020.
  21. Simcock R, Thomas T, Estes C, et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020; 22: 55–68.
  22. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011; 100(1): 93–100.
  23. Brunt AM, Haviland J, Wheatley D, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet. 2020.
  24. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. 2019; 20(3): 352–360.
  25. COVID-19 Guidelines for Triage of Breast Cancer Patients. American College of Surgeons, ACS. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer.
  26. Dietz J, Moran M, Isakoff S, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487–497.
  27. Clinical guide for the management of essential cancer surgery for adults during the coronavirus pandemic, 7 April 2020 Version 1, Publications approval reference: 001559. Academy of Medical Royal Colleges. . https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0239-Specialty-guide-Essential-Cancer-surgery-and-coronavirus-v1-70420.pdf.
  28. Cuzick J, Sestak I, Forbes J, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet. 2014; 383(9922): 1041–1048.
  29. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90(18): 1371–1388.
  30. Hwang E, Hyslop T, Hendrix L, et al. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). J Clin Oncol. 2020; 38(12): 1284–1292.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory